No abstract

A single, high dose (20 mg) of rosuvastatin prior to PCI reduces postprocedural myocardial injury in patients with ACS, with a concomitant attenuation of the postprocedural increase in hs-CRP and IL-6 levels.

Taken together, these results revealed that Mangiferin suppressed ER stress-associated NLRP3 inflammasome activation in PVAT through regulation of AMPK activity, which prevented endothelial insulin resistance. These findings suggested that the amelioration of PVAT dysfunction may be a therapeutic strategy for the prevention of endothelial insulin resistance.

No abstract

Background: LCZ696 (sacubitril/valsartan), a first-in-class angiotensin receptor-neprilysin inhibitor, can significantly reduce blood pressure in patients with heart failure. We performed this meta-analysis to determine the antihypertensive effect of LCZ696 in patients with hypertension. Methods: Randomized controlled trials were searched in MED-LINE, the Cochrane Library, and Clinicaltrials.gov. Twelve studies with a total of 6,064 participants were included. Results: Compared with angiotensin receptor blockers (ARBs), LCZ696 100 mg caused a significant reduction in systolic blood pressure (SBP) (mean difference [MD]-1.58 mm Hg, 95% confidence interval [CI]-2.09 to-1.07, p < 0.05) and diastolic blood pressure (DBP) (MD-0.66 mm Hg, 95% CI-0.98 to-0.33, p < 0.05). LCZ696 200 mg caused a significant reduction in SBP (MD-4.94 mm Hg, 95% CI-6.54 to-3.35, p < 0.05), DBP (MD-2.24 mm Hg, 95% CI-2.74 to-1.75, p < 0.05), 24-h ambulatory SBP (24 h ASBP; MD-3.69 mm Hg, 95% CI-4.80 to-2.58, p < 0.05), and 24-h ADBP (MD-1.71 mm Hg, 95% CI-2.13 to-1.28, p < 0.05). LCZ696 400 mg caused a significant reduction in SBP (MD-6.25 mm Hg, 95% CI-7.90 to-4.61, p < 0.05), DBP (MD-2.30 mm Hg, 95% CI-2.80 to-1.80, p < 0.05), 24-h ASBP (MD-4.31 mm Hg, 95% CI-6.56 to-2.07, p < 0.05), and 24 h ADBP (MD-1.69 mm Hg, 95% CI-2.59 to-0.79, p < 0.05). Compared with LCZ696 200 mg, LCZ696 400 mg caused a significant reduction in SBP (MD 1.71 mm Hg, 95% CI 1.15 to 2.27, p < 0.05), DBP (MD 0.90 mm Hg, 95% CI 0.65 to 1.16, p < 0.05), 24-h ASBP (MD 1.50 mm Hg, 95% CI 0.84 to 2.17, p < 0.05), and 24-h ADBP (MD 0.76 mm Hg, 95% CI 0.47 to 1.06, p < 0.05). Conclusions: The blood pressure-lowering effect of LCZ696 is dose-related. This meta-analysis confirms the antihypertensive effects of LCZ696.